RT Journal Article
SR Electronic
T1 Oral Carcinogenesis Is not Achieved in Different Carcinogen-treated PAI-1 Transgenic and Wild-type Mouse Models
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1001
OP 1005
VO 26
IS 6
A1 AVGOUSTIDIS, DIMITRIS
A1 NISYRIOS, THEMISTOKLIS
A1 NKENKE, EMEKA
A1 LIJNEN, ROGER
A1 RAGOS, VASSILIS
A1 PERREA, DESPINA
A1 DONTA, ISMINI
A1 VAENA, APOSTOLIA
A1 YAPIJAKIS, CHRISTOS
A1 VAIRAKTARIS, ELEFTHERIOS
YR 2012
UL http://iv.iiarjournals.org/content/26/6/1001.abstract
AB Aim: In an effort to assess the role of plasminogen activator inhibitor-1 (PAI-1) in oral squamous cancer development and progression, two different carcinogen treatment protocols were conducted. Materials and Methods: Protocol I included mice from a PAI-1 transgenic (Tg) breed (n=56) and their wild-type (WT) counterparts (n=56), divided into one control group and two main experimental groups, treated with 7,12-dimethylbenz[a]anthracene (DMBA) for 8 and 16 weeks, respectively. Protocol II included the same number and types of animals and groups, which were similarly treated with 4-Nitroquinoline 1-oxide (4-NQO) in drinking water. Two drugs that affect plasma PAI-1 levels, enalapril and pravastatin, were administered to certain subgroups of animals in both protocols. Results: None of the animals developed macroscopically-visible oral cancer lesions. Eleven animals under Protocol I and 52 animals under Protocol II died. Skin lesions were noted only in DMBA-treated animals (n=9). Almost all animals administered with 4-NQO developed alopecia and lost weight, while two of them developed stomach tumours, and one female mouse developed a large ovarian cyst. Conclusion: Transgenic mice may respond differently when used in well-established carcinogen models and oral carcinogenesis is hard to achieve in these rodents.